Fernando A Gonzales-Zubiate

Dr. Fernando A Gonzales-Zubiate

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Journal of Molecular Biology
Verified
Journal Article
Closed access
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
NZNilson I.T. Zanchin
Nilson I.T. Zanchin
JLJuliana S. Luz
Juliana S. Luz
COCarla Oliveira
Carla Oliveira

1 January 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MSMahavir Singh
Mahavir Singh
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
DCDuilio Cascio
Duilio Cascio
NHNathanael Heckmann
Nathanael Heckmann
GCGuillaume Chanfreau
Guillaume Chanfreau
JFJuli Feigon
Juli Feigon
H/ACA ribonucleoprotein particles are essential for ribosomal RNA and telomerase RNA processing and metabolism. Shq1p has been identified as an essential eukaryotic H/ACA small nucleolar (sno) ribonucleoparticle (snoRNP) biogenesis and assembly factor. Shq1p is postulated to be involved in the early biogenesis steps of H/ACA snoRNP complexes, and Shq1p depletion leads to a specific decrease in H/ACA small nucleolar RNA levels and to defects in ribosomal RNA processing. Shq1p contains two predicted domains as follows: an N-terminal CS (named after CHORD-containing proteins and SGT1) or HSP20-like domain, and a C-terminal region of high sequence homology called the Shq1 domain. Here we report the crystal structure and functional studies of the Saccharomyces cerevisiae Shq1p CS domain. The structure consists of a compact anti-parallel β-sandwich fold that is composed of two β-sheets containing four and three β-strands, respectively, and a short α-helix. Deletion studies showed that the CS domain is required for the essential functions of Shq1p. Point mutations in residues Phe-6, Gln-10, and Lys-80 destabilize Shq1p in vivo and induce a temperature-sensitive phenotype with depletion of H/ACA small nucleolar RNAs and defects in rRNA processing. Although CS domains are frequently found in co-chaperones of the Hsp90 molecular chaperone, no interaction was detected between the Shq1p CS domain and yeast Hsp90 in vitro. These results show that the CS domain is essential for Shq1p function in H/ACA snoRNP biogenesis in vivo, possibly in an Hsp90-independent manner.

15 August 2005 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
DGDaniela C. Granato
Daniela C. Granato
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
JLJuliana S. Luz
Juliana S. Luz
FCFlávia Cassiola
Flávia Cassiola
GMGlaucia Maria Machado-Santelli
Glaucia Maria Machado-Santelli
COCarla Oliveira
Carla Oliveira
In eukaryotes, pre‐rRNA processing depends on a large number of nonribosomal trans‐acting factors that form large and intriguingly organized complexes. A novel nucleolar protein, Nop53p, was isolated by using Nop17p as bait in the yeast two‐hybrid system. Nop53p also interacts with a second nucleolar protein, Nip7p. A carbon source‐conditional strain with the NOP53 coding sequence under the control of the GAL1 promoter did not grow in glucose‐containing medium, showing the phenotype of an essential gene. Under nonpermissive conditions, the conditional mutant strain showed rRNA biosynthesis defects, leading to an accumulation of the 27S and 7S pre‐rRNAs and depletion of the mature 25S and 5.8S mature rRNAs. Nop53p did not interact with any of the exosome subunits in the yeast two‐hybrid system, but its depletion affects the exosome function. In pull‐down assays, protein A‐tagged Nop53p coprecipitated the 27S and 7S pre‐rRNAs, and His–Nop53p also bound directly 5.8S rRNA in vitro, which is consistent with a role for Nop53p in pre‐rRNA processing.

20 August 2013 in RNA
Verified
Journal Article
Open access
PDF file
CSCyril Saguez
Cyril Saguez
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
MSManfred Schmid
Manfred Schmid
ABAndreas Bøggild
Andreas Bøggild
CLChrysa M. Latrick
Chrysa M. Latrick
TJTorben Heick Jensen
Torben Heick Jensen
A monthly journal publishing high-quality, peer-reviewed research on all topics related to RNA and its metabolism in all organisms

1 October 2002 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
COCarla Oliveira
Carla Oliveira
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
NZNilson I. T. Zanchin
Nilson I. T. Zanchin
Rrp43p is a Saccharomycescerevisiae exosome subunit involved in pre‐rRNA processing which is found both in the nucleus and in the cytoplasm. So far, no function has been assigned to the cytoplasmic fraction of Rrp43p. We have addressed Rrp43p function by analyzing mRNA stability in three rrp43 temperature‐sensitive ( ts ) strains, which carry different ts alleles ( rrp43‐1 , rrp43‐2 and rrp43‐3 ), and by analyzing Rrp43p interactions with the remaining exosome subunits. In the ts strains, endogenous mRNAs ( ACT1 and PAB1 ), as well as a heterologous reporter mRNA ( CATpG ) showed longer half‐lives, relative to a control strain carrying wild‐type RRP43 . The mutants also accumulated a degradation intermediate of the reporter mRNA that is typical of defective mRNA decay. These results allow us to propose that Rrp43p is required for mRNA degradation. Rrp43p interacts with the exosome complex via Rrp46p, as determined by two‐hybrid analyses. Interestingly, the rrp43ts mutant proteins do not interact with Rrp46p, indicating that the ts phenotype may be caused by disruption of the Rrp43p– Rrp46p interaction. The ts strains also showed a pre‐rRNA processing defect, which is consistent with previous studies on Rrp43p function.

31 August 2021 in Journal of Industrial Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
EMEvelyn C Mollocana-Lara
Evelyn C Mollocana-Lara
MNMing Ni
Ming Ni
Spiros N. AgathosSpiros N. Agathos
Spiros N. Agathos
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
Although the study of ribonucleic acid (RNA) therapeutics started decades ago, for many years, this field of research was overshadowed by the growing interest in DNA-based therapies. Nowadays, the role of several types of RNA in cell regulation processes and the development of various diseases have been elucidated, and research in RNA therapeutics is back with force. This short literature review aims to present general aspects of many of the molecules currently used in RNA therapeutics, including in vitro transcribed mRNA (IVT mRNA), antisense oligonucleotides (ASOs), aptamers, small interfering RNAs (siRNAs), and microRNAs (miRNAs). In addition, we describe the state of the art of technologies applied for synthetic RNA manufacture and delivery. Likewise, we detail the RNA-based therapies approved by the FDA so far, as well as the ongoing clinical investigations. As a final point, we highlight the current and potential advantages of working on RNA-based therapeutics and how these could lead to a new era of accessible and personalized healthcare.